{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:24:03Z","timestamp":1757618643438,"version":"3.44.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03171-1","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T20:52:42Z","timestamp":1752180762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tislelizumab-induced anaphylactic shock: a case report"],"prefix":"10.1007","volume":"16","author":[{"given":"Haiyu","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feixue","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanwen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"3171_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","volume":"29","author":"SY Liu","year":"2020","unstructured":"Liu SY, Wu YL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020;29:1355\u201364.","journal-title":"Expert Opin Investig Drugs"},{"key":"3171_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15569527.2023.2275028","volume":"43","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin L, Zhang T, Gao R, Zou K, Fu M, et al. Literature analysis of cutaneous adverse reactions induced by Tislelizumab. Cutan Ocul Toxicol. 2024;43:52\u20137.","journal-title":"Cutan Ocul Toxicol"},{"key":"3171_CR3","first-page":"2700166","volume":"2022","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen J, Li Q, Li N, Yu J, Liu F. The effects of axitinib plus Tislelizumab in the treatment of advanced renal cell carcinoma. J Oncol. 2022;2022:2700166.","journal-title":"J Oncol"},{"key":"3171_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34:533\u201342.","journal-title":"Leukemia"},{"key":"3171_CR5","doi-asserted-by":"publisher","first-page":"107327482211112","DOI":"10.1177\/10732748221111296","volume":"29","author":"L Zhang","year":"2022","unstructured":"Zhang L, Geng Z, Hao B, Geng Q, Tislelizumab. A modified Anti-tumor programmed death receptor 1 antibody. Cancer Control: J Moffitt Cancer Cent. 2022;29:10732748221111296.","journal-title":"Cancer Control: J Moffitt Cancer Cent"},{"key":"3171_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcgammaRs modulate the Anti-tumor activity of antibodies targeting the PD-1\/PD-L1 Axis. Cancer Cell. 2015;28:285\u201395.","journal-title":"Cancer Cell"},{"key":"3171_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67:1079\u201390.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"3171_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, et al. Tislelizumab vs Sorafenib as First-Line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial. JAMA Oncol. 2023;9:1651\u20139.","journal-title":"JAMA Oncol"},{"key":"3171_CR9","doi-asserted-by":"publisher","first-page":"1347896","DOI":"10.3389\/fonc.2024.1347896","volume":"14","author":"B Yang","year":"2024","unstructured":"Yang B, Gou W, Lan N, Shao Q, Hu W, Xue C, et al. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report. Front Oncol. 2024;14:1347896.","journal-title":"Front Oncol"},{"key":"3171_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12890-024-03140-4","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Lan H, Mao X, Chen Y. Pituitary-adrenal axis dysfunction induced by Tislelizumab immunotherapy for non-small cell lung cancer: a case series and literature review. BMC Pulm Med. 2024;24:327.","journal-title":"BMC Pulm Med"},{"key":"3171_CR11","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"key":"3171_CR12","doi-asserted-by":"crossref","unstructured":"Zhou Y, Xue H, Lu C, Zhang Y, Wu Q, Zhang J et al. Treatment of Tislelizumab-Induced toxic epidermal necrolysis and agranulocytosis: a case report and literature review. Current drug safety 2024.","DOI":"10.2174\/0115748863297885240604111018"},{"key":"3171_CR13","doi-asserted-by":"crossref","unstructured":"Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z et al. EClinicalMedicine. Fecal microbiota transplantation plus Tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). 2023;66:102315.","DOI":"10.1016\/j.eclinm.2023.102315"},{"key":"3171_CR14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(05)67569-1","volume":"366","author":"DM Jackman","year":"2005","unstructured":"Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366:1385\u201396.","journal-title":"Lancet"},{"key":"3171_CR15","doi-asserted-by":"publisher","first-page":"644434","DOI":"10.3389\/fonc.2021.644434","volume":"11","author":"T Yuan","year":"2021","unstructured":"Yuan T, Wang X, Sun S, Cao Z, Feng X, Gao Y. Profiling of 520 candidate genes in 50 surgically treated Chinese small cell lung Cancer patients. Front Oncol. 2021;11:644434.","journal-title":"Front Oncol"},{"key":"3171_CR16","doi-asserted-by":"crossref","unstructured":"Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y et al. Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer 2020;8.","DOI":"10.1136\/jitc-2019-000453"},{"key":"3171_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.36290\/vnl.2019.029","volume":"65","author":"I Krcmova","year":"2019","unstructured":"Krcmova I, Novosad J.[Anaphylactic symptoms and anaphylactic shock. Vnitr Lek. 2019;65:149\u201356.","journal-title":"Vnitr Lek"},{"key":"3171_CR18","doi-asserted-by":"crossref","unstructured":"Green S, Krupowicz B, Capon M, Lindberg A, Kulkarni A, Li J. Serum tryptase changes in children with suspected perioperative hypersensitivity. Comment BJA Open. 2024; 9: 100254. BJA open 2024;12:100307.","DOI":"10.1016\/j.bjao.2024.100307"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03171-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03171-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03171-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:44:39Z","timestamp":1757220279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03171-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03171-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted an exemption from requiring ethics approval by the Ethics Committee of Lanzhou University Second Hospital, as it was an observational report. All human data were collected in accordance with the guidelines of the 1964 Declaration of Helsinki, and written informed consent for study participation was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient for publication of this report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1303"}}